OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
NCT ID: NCT00036647
Last Updated: 2018-01-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
731 participants
INTERVENTIONAL
2001-11-01
2004-01-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Ph II OSI-774 (Erlotinib,Tarceva) In Advanced Bronchioloalveolar Cell Lung Cancer
NCT00590902
OSI-774 (Erlotinib, Tarceva) in Elderly Patients
NCT00200395
Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer
NCT00072631
Study of OSI-774 (Tarceva) in Previously Untreated Elderly Lung Cancer Patients
NCT00137800
Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy
NCT01186861
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tarceva (erlotinib HCl, OSI-774 )
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Canadian Cancer Trials Group
NETWORK
OSI Pharmaceuticals
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Frances Shephard, M.D.
Role: PRINCIPAL_INVESTIGATOR
Princess Margaret Hospital, Canada
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Chicago Medical Center
Chicago, Illinois, United States
University of Washington
Seattle, Washington, United States
Centro Medico Confidence
Buenos Aires, CP, Argentina
Hospital Britanico
Buenos Aires, , Argentina
Hospital Interzonal de Agudos Evita
Buenos Aires, , Argentina
Instituto Alexander fleming
Buenos Aires, , Argentina
Hospital Churruca Visca
Buenos Aires, , Argentina
Instituto Oncologico Angel Roffo
Capital Federal, , Argentina
Hospital Italiano
Capital Federal, , Argentina
Canberra Hospital- Australia
Woden, Australian Capital Territory, Australia
Prince of Wales Hospital
Randwick, New South Wales, Australia
Newcastle Mater Misericordiae Hospital
Waratah, New South Wales, Australia
Southern Medical Day Care Center
Wollongong, New South Wales, Australia
Western Hospital
Footscray, Victoria, Australia
The Royal Melbourne Hospital
Parkville, Victoria, Australia
Sir Charles Gairdner Hospital
Nedlands, Western Australia, Australia
Royal Adelaide Hospital
South Australia, , Australia
Peter MacCallum Cancer Institute
Victoria, , Australia
Austin & Repatriation Medical Centre
Victoria, , Australia
Instituto do Cancer do Ceara
Fortaleza, CEP, Brazil
Instituto Nacional de Cancerologia
Rio de Janeiro, CEP, Brazil
Nucleo de Oncologia da Bahia
Salvador, Estado de Bahia, Brazil
Hospital Vera Cruz S/A
Belo Horizonte, MG CEP, Brazil
Irmandade Santa Casa de Miseicordia de Porto
Porto Alegre, RS CEP, Brazil
Hospital Sao Lucas da PUCRS
Porto Alegre, RS CEP, Brazil
Faculdade de Medicina do ABC
Santo André, SP CEP, Brazil
Escola Paulista de Medicina
São Paulo, SP CEP, Brazil
Instituto do Cancer Arnaldo Vieira de Carvalho
São Paulo, São Paulo, Brazil
Tom Baker Cancer Centre
Calgary, Alberta, Canada
Cross Cancer Institute
Edmonton, Alberta, Canada
Cancer Centre for the Southern Interior
Kelowna, British Columbia, Canada
BCCA - Vancouver Island
Victoria, British Columbia, Canada
CancerCare Manitoba (CCMB)
Winnipeg, Manitoba, Canada
Dr.H. Bliss Murphy Cancer Centre
St. John's, Newfoundland and Labrador, Canada
QEII Health Sciences Centre
Halifax, Nova Scotia, Canada
The Royal Victoria Hospital
Barrie, Ontario, Canada
Northeastern Ontario Regional Cancer Centre
Greater Sudbury, Ontario, Canada
Hamilton Regional Cancer Centre
Hamilton, Ontario, Canada
Kingston Regional Cancer Centre
Kingston, Ontario, Canada
Credit Valley Hospital
Missisauga, Ontario, Canada
Southlake Regional Health Centre
Newmarket, Ontario, Canada
Ottawa Regional Cancer Centre
Ottawa, Ontario, Canada
Peterborough Regional Health Centre
Peterborough, Ontario, Canada
Hotel Dieu Health Sciences Hospital
Saint Catherines, Ontario, Canada
Group Health Centre
Sault Saint Marie, Ontario, Canada
Toronto East General Hospital
Toronto, Ontario, Canada
Toronto-Sunnybrook Reg.Canc.Center
Toronto, Ontario, Canada
Mount Sinai Hospital
Toronto, Ontario, Canada
Princess Margaret Hospital
Toronto, Ontario, Canada
Humbar River Regional Hospital
Weston, Ontario, Canada
Hopital Notre-Dame du CHUM
Montreal, Quebec, Canada
McGill University
Montreal, Quebec, Canada
Hopital Du Sacre - Coeur De Montreal
Montreal, Quebec, Canada
Hopital Laval
Ste-Foy, Quebec, Canada
Allan Blair Cancer Centre
Regina, Saskatchewan, Canada
Institution: Clinica Las Condes
Santiago, , Chile
Pamela Youde Nethersole Easter Hospital
Hong Kong, , China
Queen Mary Hospital
Hong Kong, , China
Lungenklinik Heckeshorn
Berlin, , Germany
Asklepios Fachkiniken
Gauting, , Germany
Zentrum fur pheulmologie und Thoraxchirurgie
Großhansdorf, , Germany
Thoraxklinik Heidelberg
Heidelberg, , Germany
Lungenklinik Hermer
Hermer, , Germany
Sotiria Hospital
Athens, , Greece
Haemek Medical Center
Afula, , Israel
RAMBAM Medical Center
Haifa, , Israel
Rabin Medical Center Beilinson Campus
Petach-Tiqva, , Israel
Rabin Medical Center Golda Campus
Petach-Tiqva, , Israel
Kaplan Medical Center
Rehovot, , Israel
Sourasky Medical Center Oncology Institute
Tel Aviv, , Israel
Sheba Medical Center Oncology Day Care
Tel Litwinsky, , Israel
Assaf Harofeh Medical Center
Ẕerifin, , Israel
Instituto Nacional de Cancerologia
Mexico City, CP, Mexico
Centro Estatal de Cancerologia de Durango
Durango, , Mexico
Hospital Central Sur de Alta Especialidad, PEMEX
Mexico City, , Mexico
Wellington Hospital
Riddiford Street, Wellington Region, New Zealand
Greenlane Hospital - New Zealand
Auckland, , New Zealand
Oncology Institute Bucharest
Bucharest, , Romania
Oncology Institute Ion Chiricuta
Cluj-Napoca, , Romania
Spitalul Universitar
Iași, , Romania
Clinical County Hospital
Sibiu, , Romania
National University Hospital
Singapore, , Singapore
National Cancer Centre - Singapore
Singapore, , Singapore
Durban Oncology Centre
Westbridge, Durban, South Africa
Die Wilgers Hospital
Lynnwood, Pretoria, South Africa
Oncotherapy Dept, National Hospital
Bloemfontein, , South Africa
Sandton Oncology Centre
Parklands, , South Africa
Johannesburg Hospital
Parktown, , South Africa
Eastern Cape Oncology Centre
Port Elizabeth, , South Africa
Mary Potter Oncology Centre
Pretoria, , South Africa
University of Pretoria
Pretoria, , South Africa
Rosebank Clinic Oncology Unit
Rosebank, , South Africa
Lund University Hospital
Lund, , Sweden
Sahlgrenska University Hospital
Lund, , Sweden
Pramongkutklao Hospital
Phayathai, Bangkok, Thailand
Div. of Med Onc. The National Cancer Institute of Thailand
Bangkok, , Thailand
Chiangmai University
Chiang Mai, , Thailand
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P, Seymour L; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005 Jul 14;353(2):123-32. doi: 10.1056/NEJMoa050753.
Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, Lorimer I, Zhang T, Liu N, Daneshmand M, Marrano P, da Cunha Santos G, Lagarde A, Richardson F, Seymour L, Whitehead M, Ding K, Pater J, Shepherd FA. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med. 2005 Jul 14;353(2):133-44. doi: 10.1056/NEJMoa050736.
Related Links
Access external resources that provide additional context or updates about the study.
Link to results on Astellas Clinical Study Results website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BR.21
Identifier Type: -
Identifier Source: org_study_id
NCT00026325
Identifier Type: -
Identifier Source: nct_alias
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.